|
시장보고서
상품코드
1556595
만성 부비동염 시장 보고서 : 동향, 예측, 경쟁 분석(-2030년)Chronic Rhinosinusitis Market Report: Trends, Forecast and Competitive Analysis to 2030 |
||||||
Lucintel
만성 부비동염의 동향 및 예측
세계의 만성 부비동염 시장은 2024년부터 2030년까지 연평균 복합 성장률(CAGR) 7.5%로 성장할 것으로 예측됩니다. 이 시장의 주요 촉진요인은 임상시험 수 증가, 혁신적인 치료 접근법에 대한 요구 증가, 진단 도구의 지속적인 기술 진보입니다. 세계 만성 부비동염 시장의 미래는 병원, 전문 클리닉, 외래수술센터(ASC) 시장에서의 기회에 의해 유망시되고 있습니다.
부문별 만성 부비동염
본 조사에서는 세계 만성 부비동염의 치료 유형별, 질환 표현형별, 최종 용도별, 지역별 예측을 제공합니다.
만성 부비동염 시장 인사이트
Lucintel은 스테로이드 점비약이 예측 기간 동안 가장 높은 성장을 이룰 것으로 예측했습니다.
이 시장에서 병원은 예측 기간 동안 가장 높은 성장을 보일 것으로 예상됩니다.
북미는 예측기간 동안 가장 높은 성장이 예상됩니다.
FAQ
Q1. 시장의 성장 예측은 :
A1. 세계의 만성 부비동염 시장은 2024년부터 2030년까지 연평균 복합 성장률(CAGR) 7.5%로 성장할 것으로 예측됩니다.
Q2. 시장 성장에 영향을 미치는 주요 촉진요인은 :
A2. 만성 부비동염 시장의 주요 촉진요인은 임상시험 수 증가, 혁신적인 치료 접근법에 대한 요구 증가, 진단 도구의 지속적인 기술 진보입니다.
Q3. 시장의 주요 부문은 :
A3. 만성 부비동염 시장의 미래는 병원, 전문 클리닉, 외래수술센터(ASC) 시장에서의 기회에 의해 유망시되고 있습니다.
Q4. 시장의 주요 기업은 :
A4. 만성 부비동염의 주요 기업의 일부는 다음과 같습니다.
- Lyra Therapeutics
- Novartis
- Medtronic
- GlaxoSmithKline
- AstraZeneca
- Sanofi
- Dr. Reddy's Laboratories
- Stryker Corporation
- Bayer
- Smith & Nephew
Q5. 향후 가장 큰 시장 부문은 :
A5. Lucintel은 스테로이드 점비약이 예측 기간 동안 가장 높은 성장을 이룰 것으로 예측했습니다.
Q6. 시장에서 향후 5년간 최대가 될 것으로 예상되는 지역은 :
A6. 예측기간 동안 북미가 가장 높은 성장이 예상됩니다.
Q7. 보고서 사용자 정의는 가능한가?
A7. 그렇습니다, Lucintel는 추가 비용 없이 10% 주문을 받아서 만듭니다.
목차
제1장 주요 요약
제2장 세계의 만성 부비동염 시장 : 시장 역학
- 서문, 배경 및 분류
- 공급망
- 업계의 촉진요인 및 과제
제3장 시장 동향 및 예측 분석(2018-2030년)
- 거시경제 동향(2018-2023년)과 예측(2024-2030년)
- 세계의 만성 부비동염 시장 동향(2018-2023년)과 예측(2024-2030년)
- 세계의 만성 부비동염 시장 : 치료 유형별
- 의료기기
- 약물
- 점비약
- 스테로이드 점비약
- 수술
- 기타
- 세계의 만성 부비동염 시장 : 질병 표현형별
- 비호산구성 만성 부비동염
- 호산구성 만성 부비동염
- 감염성 만성 부비동염
- 알레르기성 진균성 부비동염
- 기타
- 세계의 만성 부비동염 시장 규모 : 최종 용도별
- 병원
- 전문 클리닉
- 외래수술센터(ASC)
- 기타
제4장 시장 동향 및 예측 분석(2018-2023년) : 지역별
- 지역별 세계의 만성 부비동염 시장
- 북미의 만성 부비동염 시장
- 유럽의 만성 부비동염 시장
- 아시아태평양의 만성 부비동염 시장
- 기타 지역의 만성 부비동염 시장
제5장 경쟁 분석
- 제품 포트폴리오 분석
- 운영 통합
- Porter's Five Forces 분석
제6장 성장 기회 및 전략 분석
- 성장 기회 분석
- 치료 유형별 세계 만성 부비동염 시장의 성장 기회
- 질병 표현형별 세계 만성 부비동염 시장의 성장 기회
- 최종 용도별 세계 만성 부비동염 시장의 성장 기회
- 지역별 세계 만성 부비동염 시장의 성장 기회
- 세계 만성 부비동염 시장의 새로운 동향
- 전략 분석
- 신제품 개발
- 세계 만성 부비동염 시장의 능력 확대
- 세계 만성 부비동염 시장의 합병, 인수 및 합작 사업
- 인증 및 라이선싱
제7장 주요 기업의 기업 프로파일
- Lyra Therapeutics
- Novartis
- Medtronic
- GlaxoSmithKline
- AstraZeneca
- Sanofi
- Dr. Reddy's Laboratories
- Stryker Corporation
- Bayer
- Smith & Nephew
Chronic Rhinosinusitis Trends and Forecast
The future of the global chronic rhinosinusitis market looks promising with opportunities in the hospital, specialty clinic, and ambulatory surgical center markets. The global chronic rhinosinusitis market is expected to grow with a CAGR of 7.5% from 2024 to 2030. The major drivers for this market are growing number of clinical trials, rise in the need for innovative therapeutic approaches, and ongoing technological advancements in diagnostic tools.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Chronic Rhinosinusitis by Segment
The study includes a forecast for the global chronic rhinosinusitis by treatment type, disease phenotype, end use, and region.
Chronic Rhinosinusitis Market by Treatment Type [Shipment Analysis by Value from 2018 to 2030]:
- Medical Devices
- Drugs
- Nasal Drops
- Steroid Nasal Sprays
- Surgery
- Others
Chronic Rhinosinusitis Market by Disease Phenotype [Shipment Analysis by Value from 2018 to 2030]:
- Non-Eosinophilic Chronic Rhinosinusitis
- Eosinophilic Chronic Rhinosinusitis
- Infectious Chronic Rhinosinusitis
- Allergic Fungal Rhinosinusitis
- Others
Chronic Rhinosinusitis Market by End Use [Shipment Analysis by Value from 2018 to 2030]:
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Others
Chronic Rhinosinusitis Market by Region [Shipment Analysis by Value from 2018 to 2030]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
List of Chronic Rhinosinusitis Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies chronic rhinosinusitis companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the chronic rhinosinusitis companies profiled in this report include-
- Lyra Therapeutics
- Novartis
- Medtronic
- GlaxoSmithKline
- AstraZeneca
- Sanofi
- Dr. Reddy's Laboratories
- Stryker Corporation
- Bayer
- Smith & Nephew
Chronic Rhinosinusitis Market Insights
Lucintel forecasts that steroid nasal spray is expected to witness the highest growth over the forecast period.
Within this market, hospital is expected to witness the highest growth over the forecast period.
North America is expected to witness the highest growth over the forecast period.
Features of the Global Chronic Rhinosinusitis Market
Market Size Estimates: Chronic rhinosinusitis market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Chronic rhinosinusitis market size by treatment type, disease phenotype, end use, and region in terms of value ($B).
Regional Analysis: Chronic rhinosinusitis market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different treatment types, disease phenotypes, end uses, and regions for the chronic rhinosinusitis market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the chronic rhinosinusitis market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
FAQ
Q1. What is the growth forecast for chronic rhinosinusitis market?
Answer: The global chronic rhinosinusitis market is expected to grow with a CAGR of 7.5% from 2024 to 2030.
Q2. What are the major drivers influencing the growth of the chronic rhinosinusitis market?
Answer: The major drivers for this market are growing number of clinical trials, rise in the need for innovative therapeutic approaches, and ongoing technological advancements in diagnostic tools.
Q3. What are the major segments for chronic rhinosinusitis market?
Answer: The future of the chronic rhinosinusitis market looks promising with opportunities in the hospital, specialty clinic, and ambulatory surgical center markets.
Q4. Who are the key chronic rhinosinusitis market companies?
Answer: Some of the key chronic rhinosinusitis companies are as follows:
- Lyra Therapeutics
- Novartis
- Medtronic
- GlaxoSmithKline
- AstraZeneca
- Sanofi
- Dr. Reddy's Laboratories
- Stryker Corporation
- Bayer
- Smith & Nephew
Q5. Which chronic rhinosinusitis market segment will be the largest in future?
Answer: Lucintel forecasts that steroid nasal spray is expected to witness the highest growth over the forecast period.
Q6. In chronic rhinosinusitis market, which region is expected to be the largest in next 5 years?
Answer: North America is expected to witness the highest growth over the forecast period.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
- Q.1. What are some of the most promising, high-growth opportunities for the chronic rhinosinusitis market by treatment type (medical devices, drugs, nasal drops, steroid nasal sprays, surgery, and others), disease phenotype (non-eosinophilic chronic rhinosinusitis, eosinophilic chronic rhinosinusitis, infectious chronic rhinosinusitis, allergic fungal rhinosinusitis, and others), end use (hospitals, specialty clinics, ambulatory surgical centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
- Q.2. Which segments will grow at a faster pace and why?
- Q.3. Which region will grow at a faster pace and why?
- Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
- Q.5. What are the business risks and competitive threats in this market?
- Q.6. What are the emerging trends in this market and the reasons behind them?
- Q.7. What are some of the changing demands of customers in the market?
- Q.8. What are the new developments in the market? Which companies are leading these developments?
- Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
- Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
- Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
Table of Contents
1. Executive Summary
2. Global Chronic Rhinosinusitis Market : Market Dynamics
- 2.1: Introduction, Background, and Classifications
- 2.2: Supply Chain
- 2.3: Industry Drivers and Challenges
3. Market Trends and Forecast Analysis from 2018 to 2030
- 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
- 3.2. Global Chronic Rhinosinusitis Market Trends (2018-2023) and Forecast (2024-2030)
- 3.3: Global Chronic Rhinosinusitis Market by Treatment Type
- 3.3.1: Medical Devices
- 3.3.2: Drugs
- 3.3.3: Nasal Drops
- 3.3.4: Steroid Nasal Sprays
- 3.3.5: Surgery
- 3.3.6: Others
- 3.4: Global Chronic Rhinosinusitis Market by Disease Phenotype
- 3.4.1: Non-Eosinophilic Chronic Rhinosinusitis
- 3.4.2: Eosinophilic Chronic Rhinosinusitis
- 3.4.3: Infectious Chronic Rhinosinusitis
- 3.4.4: Allergic Fungal Rhinosinusitis
- 3.4.5: Others
- 3.5: Global Chronic Rhinosinusitis Market by End Use
- 3.5.1: Hospitals
- 3.5.2: Specialty Clinics
- 3.5.3: Ambulatory Surgical Centers
- 3.5.4: Others
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
- 4.1: Global Chronic Rhinosinusitis Market by Region
- 4.2: North American Chronic Rhinosinusitis Market
- 4.2.1: North American Chronic Rhinosinusitis Market by Treatment Type: Medical Devices, Drugs, Nasal Drops, Steroid Nasal Sprays, Surgery, and Others
- 4.2.2: North American Chronic Rhinosinusitis Market by End Use: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others
- 4.3: European Chronic Rhinosinusitis Market
- 4.3.1: European Chronic Rhinosinusitis Market by Treatment Type: Medical Devices, Drugs, Nasal Drops, Steroid Nasal Sprays, Surgery, and Others
- 4.3.2: European Chronic Rhinosinusitis Market by End Use: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others
- 4.4: APAC Chronic Rhinosinusitis Market
- 4.4.1: APAC Chronic Rhinosinusitis Market by Treatment Type: Medical Devices, Drugs, Nasal Drops, Steroid Nasal Sprays, Surgery, and Others
- 4.4.2: APAC Chronic Rhinosinusitis Market by End Use: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others
- 4.5: ROW Chronic Rhinosinusitis Market
- 4.5.1: ROW Chronic Rhinosinusitis Market by Treatment Type: Medical Devices, Drugs, Nasal Drops, Steroid Nasal Sprays, Surgery, and Others
- 4.5.2: ROW Chronic Rhinosinusitis Market by End Use: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others
5. Competitor Analysis
- 5.1: Product Portfolio Analysis
- 5.2: Operational Integration
- 5.3: Porter's Five Forces Analysis
6. Growth Opportunities and Strategic Analysis
- 6.1: Growth Opportunity Analysis
- 6.1.1: Growth Opportunities for the Global Chronic Rhinosinusitis Market by Treatment Type
- 6.1.2: Growth Opportunities for the Global Chronic Rhinosinusitis Market by Disease Phenotype
- 6.1.3: Growth Opportunities for the Global Chronic Rhinosinusitis Market by End Use
- 6.1.4: Growth Opportunities for the Global Chronic Rhinosinusitis Market by Region
- 6.2: Emerging Trends in the Global Chronic Rhinosinusitis Market
- 6.3: Strategic Analysis
- 6.3.1: New Product Development
- 6.3.2: Capacity Expansion of the Global Chronic Rhinosinusitis Market
- 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Chronic Rhinosinusitis Market
- 6.3.4: Certification and Licensing
7. Company Profiles of Leading Players
- 7.1: Lyra Therapeutics
- 7.2: Novartis
- 7.3: Medtronic
- 7.4: GlaxoSmithKline
- 7.5: AstraZeneca
- 7.6: Sanofi
- 7.7: Dr. Reddy's Laboratories
- 7.8: Stryker Corporation
- 7.9: Bayer
- 7.10: Smith & Nephew
